Cerenia 24 mg Tablets for Dogs

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of the veterinary medicinal product against vomiting due to motion sickness
is not recommended.
Dogs:
Although maropitant has been demonstrated to be effective in both the treatment and
prevention of emesis induced by chemotherapy, it was found more efficacious if used
preventively. Therefore, it is recommended to administer the antiemetic prior to
administration of the chemotherapeutic agent.
Cats:
The efficacy of maropitant in reduction of nausea was demonstrated in studies using
a model (xylazine induced nausea).

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in dogs less
than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or
lactating dogs and cats. Use only according to the benefit-risk assessment by the
responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14-
day treatment period due to metabolic saturation, careful monitoring of liver function
and any adverse events should be implemented during long term treatment.
The veterinary medicinal product should be used with caution in animals suffering
from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and
K-ion channels. Increases of approximately 10% in the QT interval of the ECG were
observed in a study on healthy beagle dogs administered 8 mg/kg orally; however,
such an increase is unlikely to be of clinical significance.
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
veterinary medicinal product at refrigerated temperature may reduce pain at injection.
AN: 01464/2024Page 3 of 8
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Maropitant is a neurokinin-1 (NK1) receptor antagonist that acts in the central nervous
system. The veterinary medicinal product may therefore cause nausea, dizziness and
drowsiness in case of accidental self-injection. If accidental self-injection occurs, seek
medical advice immediately and show the package leaflet or the label to the physician.
Due to the content of benzyl alcohol the veterinary medicinal product may cause mild
local irritation. Skin contact should therefore be avoided. In case of accidental
exposure, wash affected skin area with plenty of water.
The veterinary medicinal product may cause skin sensitisation. People with known
hypersensitivity to maropitant or to any of the excipients should administer the
veterinary medicinal product with caution. If you develop symptoms such as a skin rash
after accidental exposure, seek medical advice and show the physician this warning.
The veterinary medicinal product may cause eye irritation. Eye contact should be
avoided. In case of accidental eye exposure, flush the eyes with plenty of water and
seek medical attention.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.